Skip Navigation



JAC Advance Access published online on September 5, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki321
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/4/717    most recent
dki321v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Freeman, J.
Right arrow Articles by Wilcox, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freeman, J.
Right arrow Articles by Wilcox, M. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received April 11, 2005
Revised June 22, 2005
Accepted August 15, 2005

Original article

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection

Jane Freeman 1, Simon D. Baines 1, Daniela Jabes 2, and Mark H. Wilcox 1*

1 Department of Microbiology, University of Leeds and The General Infirmary, Old Medical School, Leeds, LS1 3EX, UK
2 NEeD Pharma, Via Ariberto, 17, 20123, Milano, Italy

* To whom correspondence should be addressed.
Mark H. Wilcox, E-mail: mark.wilcox{at}leedsth.nhs.uk


  Abstract

Objectives: Treatment of Clostridium difficile infection (CDI) is limited primarily to either metronidazole or vancomycin. We compared vancomycin and a novel glycolipodepsipeptide, ramoplanin, in both hamster and in vitro gut models of clindamycin-induced CDI.

Methods: We used an in vitro triple-stage chemostat model that simulates the human gut, and an in vivo hamster model, both primed with clindamycin.

Results: Clindamycin exposure elicited symptomatic disease in the hamster model, and promoted C. difficile germination and toxin production in the gut model. C. difficile germination and toxin production were not associated with depletion of gut microflora in the gut model, but were temporarily associated with subinhibitory concentrations of clindamycin. Both ramoplanin and vancomycin were associated with rapid symptom resolution in the hamster model, and rapid toxin titre decrease in the in vitro gut model. In both models of CDI, vancomycin was associated with greater persistence of C. difficile spores. C. difficile spores were recovered significantly more often from the caecal contents of vancomycin-treated (n = 19/23) compared with ramoplanin-treated (n = 6/23) hamsters (P < 0.05).

Conclusions: Results from the in vitro gut and hamster models were concordant. Ramoplanin and vancomycin were similarly effective at reducing cytotoxin production in the gut CDI model and in resolving symptoms in the hamster model. Ramoplanin may be more effective than vancomycin at killing spores and preventing spore recrudescence. These findings suggest a potential therapeutic role for ramoplanin in CDI that requires further clinical investigation.

Keywords: antibiotic-associated diarrhoea; chemostat; hamster.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br Med BullHome page
O. M. Williams and R. C. Spencer
The management of Clostridium difficile infection
Br. Med. Bull., September 1, 2009; 91(1): 87 - 110.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
U. A. Ochsner, S. J. Bell, A. L. O'Leary, T. Hoang, K. C. Stone, C. L. Young, I. A. Critchley, and N. Janjic
Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
J. Antimicrob. Chemother., May 1, 2009; 63(5): 964 - 971.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. A. Critchley, L. S. Green, C. L. Young, J. M. Bullard, R. J. Evans, M. Price, T. C. Jarvis, J. W. Guiles, N. Janjic, and U. A. Ochsner
Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
J. Antimicrob. Chemother., May 1, 2009; 63(5): 954 - 963.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. D. Baines, J. Freeman, and M. H. Wilcox
Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2202 - 2204.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. D. Baines, R. O'Connor, G. Huscroft, K. Saxton, J. Freeman, and M. H. Wilcox
Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model
J. Antimicrob. Chemother., April 1, 2009; 63(4): 838 - 839.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. D. Baines, R. O'Connor, K. Saxton, J. Freeman, and M. H. Wilcox
Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model
J. Antimicrob. Chemother., March 1, 2009; 63(3): 520 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
T Monaghan, T Boswell, and Y R Mahida
Recent advances in Clostridium difficile-associated disease
Postgrad. Med. J., March 1, 2009; 85(1001): 152 - 162.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Saxton, S. D. Baines, J. Freeman, R. O'Connor, and M. H. Wilcox
Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model
Antimicrob. Agents Chemother., February 1, 2009; 53(2): 412 - 420.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. D. Baines, R. O'Connor, K. Saxton, J. Freeman, and M. H. Wilcox
Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model
J. Antimicrob. Chemother., November 1, 2008; 62(5): 1078 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
T Monaghan, T Boswell, and Y R Mahida
Recent advances in Clostridium difficile-associated disease
Gut, June 1, 2008; 57(6): 850 - 860.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. W. Hecht, M. A. Galang, S. P. Sambol, J. R. Osmolski, S. Johnson, and D. N. Gerding
In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004
Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2716 - 2719.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Freeman, S. D. Baines, K. Saxton, and M. H. Wilcox
Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model
J. Antimicrob. Chemother., July 1, 2007; 60(1): 83 - 91.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. D. Baines, K. Saxton, J. Freeman, and M. H. Wilcox
Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model
J. Antimicrob. Chemother., November 1, 2006; 58(5): 1062 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Freeman, J. Stott, S. D. Baines, W. N. Fawley, and M. H. Wilcox
Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital
J. Antimicrob. Chemother., November 1, 2005; 56(5): 988 - 989.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.